Compare Abeona Therapeutics Inc (ABEO) vs Freeport-McMoRan Inc (FCX) Price & Performance

ABEO trades at $7.46, up 0.81% today, with a bullish technical outlook supported by moving averages but overbought RSI signals. The company reported Q2 2026 revenue of $11.4 million, missing EPS estimates, yet maintains strong profitability margins and low valuations. Recent news highlights operational challenges with ZEVASKYN rollout but positive developments like CMS NTAP status.

Outlook is mixed: analyst consensus is bullish with 67% buy ratings, but risks include execution setbacks and shareholder investigations. Investment opportunity lies in growth potential if operational issues resolve, though high volatility and negative cash flows from operations pose near-term headwinds.

FCX trades at $66.83, down 2.98% on the day, but maintains a bullish technical trend with strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $0.72 EPS. Revenue remains stable around $25.9B, while net income margin improved to 11.38% in 2026. Recent news highlights operational challenges like lower copper volumes but also growth initiatives at Grasberg and Bagdad.

The outlook is positive with a consensus price target of $73.85, implying ~10% upside. Key opportunities include exposure to high copper prices and expansion projects, while risks involve production volatility, cost pressures, and reliance on commodity cycles. The stock's valuation appears elevated with a P/E of 33.93, requiring sustained earnings growth to justify further gains.